What is the fair value of Biophytis (OTC-BPTS.Y) stock?

The current fair value estimate for Biophytis (OTC-BPTS.Y) is $0.38. This implies an estimated upside of 53.6% versus the current market price.

Is Biophytis (OTC-BPTS.Y) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 53.6% versus the current market price.

How is the financial health of Biophytis?

The current financial health read for Biophytis (OTC-BPTS.Y) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Biophytis's next earnings date?

The next earnings date currently listed for Biophytis (OTC-BPTS.Y) is September 25, 2026.

Does Biophytis (OTC-BPTS.Y) pay dividends?

The latest available data indicates no current dividend yield for Biophytis (OTC-BPTS.Y).

What is the market capitalization of Biophytis?

The current market capitalization listed for Biophytis is 18.96 M.

What is the enterprise value of Biophytis?

The current enterprise value listed for Biophytis is 27.132 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Biophytis?

The ticker symbol for Biophytis is OTC-BPTS.Y, and the stock is listed on OTC Markets.

Where is Biophytis (OTC-BPTS.Y) listed?

Biophytis (OTC-BPTS.Y) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Biophytis?

The current debt-to-total-capital ratio listed for Biophytis is 32.4%, which helps investors evaluate the company’s financing structure and leverage profile.

Biophytis (BPTSY) Fair Value & Stock Analysis

Biophytis (BPTSY)

Biophytis S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing therapies intended to slow degenerative processes and support functional outcomes in age-related diseases. Its lead candidate, BIO101, is being studied across several potential uses, including obesity, respiratory infections related to COVID-19, sarcopenia, and Duchenne muscular dystrophy. The company has a collaboration with AFM-Telethon related to BIO101 development for Duchenne muscular dystrophy, and it also works with LynxKite Technologies Pte Ltd on AI-driven drug discovery for longevity-focused therapies. The listed security is an OTC Markets depositary receipt tied to Biophytis S.A., rather than ordinary common equity.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap	Enterprise Value	Total Debt / Total Capital	Altman Z-Score	Free Cash Flow / Net Income
OTC-BPTS.Y	$0.38	53.6% Upside	Bargain	Not available	Not available	Fair	0.0%	September 25, 2026	18.96 M	27.132 M	32.4%	-25.4	79.4%